PT-141 Bremelanotide
PT-141, known clinically as bremelanotide, is a synthetic melanocortin-receptor agonist. It is approved in some countries, including the United States, for a specific form of hypoactive sexual desire disorder in premenopausal women.
It is not a general sexual-performance medicine or a treatment for every cause of low desire. Physician assessment is required to establish the diagnosis, review contraindications and verify local approval.
What Is PT-141 Bremelanotide?
Bremelanotide is a peptide medicine whose US indication concerns acquired, generalised hypoactive sexual desire disorder causing marked distress or interpersonal difficulty in premenopausal women.
The diagnosis excludes low desire better explained by another medical or psychiatric condition, relationship problems, or a medicine or substance.
How Does PT-141 Bremelanotide Work?
Bremelanotide activates melanocortin receptors, with central MC4-receptor signalling considered relevant to sexual desire.
It does not replace oestrogen or testosterone, and its exact mechanism in the approved clinical indication is not fully understood.
What Has Research Studied?
The RECONNECT phase 3 trials evaluated desire and related distress in selected premenopausal women with hypoactive sexual desire disorder.
Individual responses vary, and a physician consultation helps set realistic expectations for your situation.
Safety and Medical Supervision
Bremelanotide can temporarily increase blood pressure and reduce heart rate. It is contraindicated in uncontrolled hypertension or known cardiovascular disease.
Other concerns include nausea, headache, flushing and focal skin darkening, which may persist. A physician should review pregnancy risk, oral-medicine interactions and the approved product information.
Frequently Asked Questions
Who is bremelanotide approved for?
In the United States, the indication is acquired, generalised hypoactive sexual desire disorder in premenopausal women meeting specific diagnostic criteria. Local indications may differ.
Is PT-141 approved for erectile dysfunction?
The US bremelanotide indication does not include erectile dysfunction or general sexual-performance enhancement.
Can someone with high blood pressure use it?
Uncontrolled hypertension is a contraindication. Any blood-pressure or cardiovascular history requires physician assessment before prescribing.
Is an online PT-141 vial equivalent to an approved product?
No equivalence should be assumed. Identity, formulation, manufacturing quality and regulatory approval require verification.
References
- PubMed. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
- PubMed. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Related Peptides
Wondering Whether PT-141 Bremelanotide Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.